1. Dinutuximab beta in high-risk neuroblastoma: a profile of its use

   • Kate McKeage
   • Katherine A. Lyseng-Williamson

   Adis Drug Q&A 23 May 2018 Pages: 281 - 287

   

2. Correction to: Dinutuximab beta in high-risk neuroblastoma: a profile of its use

   • Kate McKeage
   • Katherine A. Lyseng-Williamson

   Correction 06 June 2018 Pages: 288 - 288

3. Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU

   • Katherine A. Lyseng-Williamson
   • Jürgen Behr

   Adis Drug Q&A 18 June 2018 Pages: 289 - 299

   

4. Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use

   • Katherine A. Lyseng-Williamson

   Adis Drug Q&A Open access 15 June 2018 Pages: 300 - 310

5. Manage osteoporotic pain by treating osteoporosis and taking a multidimensional approach to pain management

   • Adis Medical Writers

   Disease Management 27 March 2018 Pages: 311 - 315

6. First reports of adverse drug reactions

   Drug Reactions and Interactions 07 June 2018 Pages: 316 - 316

7. Manage cutaneous adverse effects associated with tumour necrosis factor inhibitors with topical corticosteroids and oral antibiotics

   • Adis Medical Writers

   Drug Reactions and Interactions 30 May 2018 Pages: 317 - 321

   

8. Evaluation of potential prescribing errors in patients with polypharmacy: a method to improve medication safety in ambulatory care

   • Friederike Laidig
   • Marcus May
   • Dirk O. Stichtenoth

   Original Research Article 23 April 2018 Pages: 322 - 334

   

9. Clinical treatment of chronic and episodic migraine with onabotulinumtoxinA in a real-world setting

   • Fernando Velasco-Juanes
   • Juan Carlos Gómez-Esteban
   • Iratxe Ugarriza-Serrano

   Original Research Article 20 April 2018 Pages: 335 - 343

   

10. Appropriate drug dosages in obese patients

    • Sanja Mirkov
    • Katherine A. Lyseng-Williamson

    Therapy in Practice 06 April 2018 Pages: 344 - 349

    

11. Correction to: Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20 mg/5 mg/12.5 mg fixed-dose combination in hypertension: a profile of its use

    • Katherine A. Lyseng-Williamson

    Correction 08 June 2018 Pages: 350 - 350